Vident Advisory LLC lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 82.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,217 shares of the medical device company's stock after selling 25,324 shares during the period. Vident Advisory LLC's holdings in DexCom were worth $406,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Forvis Mazars Wealth Advisors LLC boosted its stake in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. boosted its position in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after acquiring an additional 135 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its holdings in DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after buying an additional 140 shares during the period. Finally, Level Four Advisory Services LLC raised its holdings in DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after buying an additional 150 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.
Insider Buying and Selling at DexCom
In other news, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock worth $6,103,505 over the last 90 days. Insiders own 0.32% of the company's stock.
DexCom Stock Up 1.3%
Shares of DXCM stock traded up $1.10 during mid-day trading on Friday, reaching $85.96. 4,257,051 shares of the company were exchanged, compared to its average volume of 4,363,381. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $120.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $33.71 billion, a P/E ratio of 60.11, a P/E/G ratio of 2.30 and a beta of 1.43. The business's 50 day simple moving average is $74.67 and its 200 day simple moving average is $78.72.
DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the firm earned $0.32 EPS. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on DXCM shares. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. The Goldman Sachs Group started coverage on shares of DexCom in a report on Friday. They issued a "buy" rating and a $104.00 price target on the stock. Robert W. Baird cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Canaccord Genuity Group raised their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $98.32.
Read Our Latest Stock Analysis on DXCM
DexCom Profile
(
Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
